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Pleural  metastases  are  more  common  in  the  visceral  pleura
and  tend  to  be  focal  in  the  parietal  pleura  which  is  why
pleural  ﬂuid  cytology  is  a  more  sensitive  diagnostic  test  than
closed  percutaneous  pleural  biopsy.6
The  most  common  type  of  tumor  to  produce  metasta-
sis  is  the  broad  group  of  adenocarcinomas,  most  of  them
from  lung,  breast,  ovary  and  GIT.  In  the  present  study
the  most  frequent  cause  of  malignant  pleural  effusion  was
lung.  The  neoplastic  cells  showed  classical  features  of
Table  1  Distribution  of  malignancies  in  500  pleural  effusion
specimens.
No  of  neoplastic  pleural
effusions  500
(%)
350  Adenocarcinoma  (lung,
breast,  ovary  and  GIT)
70Pleural effusion cytology due to
malignancy. A combined
cytomorphological--immunocytochemical
study of 500 cases
Dear  Editor,
The  ﬁrst  step  in  the  evaluation  of  patients  with  pleural  effu
sion  is  to  determine  whether  the  effusion  is  a  transudat
or  an  exudate.  An  exudative  effusion  is  diagnosed  if  th
patient  meets  Light’s  criteria,  although  new  formulas  hav
been  proposed.1
The  serum  to  pleural  ﬂuid  protein  or  albumin  gradien
may  help  improve  categorization  of  the  occasional  tran
sudate  misidentiﬁed  as  an  exudate  by  these  criteria.  
the  patient  has  a  transudative  effusion,  therapy  should  b
directed  toward  the  underlying  cause  like  heart  failure  o
cirrhosis.  If  the  patient  has  an  exudative  effusion,  attemp
should  be  made  to  deﬁne  the  etiology.  Pneumonia,  can
cer,  tuberculosis,  and  pulmonary  embolism  account  for  mo
exudative  effusions.
Cytomorphology  is  the  hallmark  for  the  diagnosis  o
malignancy.
The  speciﬁcity  of  cytomorphology  is  very  good  and  range
from  91%  to  100%  with  an  average  of  97%.  Sensitivity  range
from  22%  to  81%  with  an  average  of  58.2%.2
Morphologic  distinction  between  reactive  mesotheli
cells  and  malignant  cells  can  be  difﬁcult.  Immunocytochem
istry  is  a  common  adjunct  method  that  serves  to  improv
the  sensitivity  and  speciﬁcity  of  cytology  diagnosis.3 W
used  Ber-EP4  and  calretinin  in  all  malignant  effusions.  Be
EP4  (epithelial  cell  adhesion  molecule)  is  the  most  commo
marker  expressed  in  all  epithelial  cells  but  not  in  mesotheli
and  hematopoietic  cells.4 Calretinin  is  expressed  in  benig
and  malignant  mesothelial  cells  but  not  in  epithelial  cells
Five  hundred  malignant  pleural  effusion  samples  receive
for  cytopathological  examination  from  500  patients  hosp
talized  at  the  University  Hospital  of  Heraklion  Crete  over
5-year  period  were  analyzed  retrospectively.Table  1  shows  distribution  of  malignancies  in  500  neoplas-
tic  pleural  effusions.
Table  2  shows  immunocytochemical  markers  expressed  in
studied  malignancies.
Cytological  examination  of  pleural  ﬂuids  is  often  the
ﬁrst  line  of  investigation  to  detect  and  type  the  neoplas-
tic  cells  based  on  their  subtle  morphological  features.550 Hodgkin  and  NHL  (B  and
T)  lymphoma
10
40 Squamous  carcinoma
(lung,  head  and  neck,
larynx,  genital  track)
8
30 Neuroendocrine  tumors
(SCLC)
6
25 Malignant  Melanoma 5
5 Mesothelioma  1
Table  2  Markers  expressed  in  studied  malignancies.
Malignancy  Markers
Metastatic  lung
adenocarcinoma
CK7,  TTF-1
Metastatic  breast  carcinoma  CK19,  Her2  neu,  PR,  ER
receptors
Non-Hodgkin’s  lymphomas PAX5  (PEL,  B-cell  type),
CD4  (T-cell  type)
Hodgkin’s  lymphomas  CD15,  CD30
Metastatic  squamous Involucrin,  CK5/6carcinoma
Metastatic  neuroendocrine
tumors
Chromogranin,
Synaptophysin,  NSE,
CD56
Malignant  melanoma  HMB45,  Melan-A
Malignant  mesotheliomas  Calretinin,  WT-1
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enocarcinoma  with  large  eccentric  nuclei,  nucleoli  and
cuolated  cytoplasm.  These  neoplastic  cells  expressed  CK7
d  TTF-1.
Metastatic  breast  cancer  cells  were  often  found  in  pleural
usions  in  our  study  expressed  CK19,  or  Her2  neu  and  PR,
 receptors.
Pleural  effusions  were  more  commonly  encountered  in
matopoietic  malignancies.  In  the  present  study  NHL  was
 most  common  cause  of  pleural  effusion  due  to  lym-
oma.  The  neoplastic  cells  expressed  PAX5  in  PEL  and  in  all
ell  lymphomas  and  CD4  in  T-cell  lymphomas.  In  Hodgkin’s
phomas  the  neoplastic  cells  expressed  CD15  and  CD30
rkers  and  the  pathognomonic  Reed-Stenberg  cells  were
casionally  observed.
Among  pleural  ﬂuids  with  metastatic  squamous  carci-
ma  SCC,  the  most  common  primary  was  lung,  head  and
ck  region,  larynx  and  female  genital  tract.  The  presence
keratinized  squamous  cells  and  pearls  were  helpful  diag-
stic  features.  In  this  study  the  helpful  markers  for  the
gnosis  of  SCC  were  involucrin  and  CK5/6.
The  most  common  neuroendocrine  tumor  was  the  SCLC
th  isolated  small  cell  or  the  characteristic  Indian-ﬁle  and
lding  of  neoplastic  cells  and  expressed  Chromogranin,
naptophysin,  NSE  and  CD56.
Pleural  effusions  due  to  malignant  melanoma  were  rare
).  The  malignant  melanoma  cells  were  isolated  or  com-
sed  of  clusters  with  large  nuclei  and  prominent  nucleoli,
d  expressed  HMB45  and  Melan-A.
In  5  cases  (1%)  of  primary  malignant  mesotheliomas  the
gnosis  was  complicated  because  the  malignant  mesothe-
l  cells  resembled  benign  cells,  but  the  clinical  history
the  patient  was  useful  for  the  correct  cytologic  diagno-
.  Bizarre  enlargement,  large  nucleoli  and  abnormal  cell
ms,  nuclear  mitoses  were  found  to  favor  malignancy.  All
lignant  cells  expressed  calretinin  and  WT-1.
Genetic  analyses  of  pleural  effusion  enhance  the  sensi-
ity  for  malignancy.  Common  features  of  early  malignancy,
ich  include  DNA  methylation,  other  mutations  and
crosatellite  alterations,  can  be  detected  by  polymerase
ain  reaction  (PCR)  and  microarray  techniques.  Detection
epidermal  growth  factor  receptor  (EGFR)  mutations  in
lignant  cells  can  predict  a  favorable  therapeutic  response
patients  with  non-small  cell  lung  cancer.  On  the  other
nd,  recognition  of  Kristen  ras  (K-ras)  oncogene  mutations
a  negative  predictor  of  responsiveness  to  EGFR  tyrosine
ase  inhibitors.7
In  2007  anaplastic  lymphoma  kinase  (ALK)  rearrangement
s  discovered  in  approximately  5%  of  non  small  cell
g  cancer  (NSCLC),  and  ALK  inhibitor  (crizotinib)  was
idly  approved  in  5  years  both  in  the  USA  and  Japan.
day  druggable  oncogenes  other  than  EGFR  and  ALK  have
en  detected  and  development  of  speciﬁc  inhibitors  is
derway.8
In  conclusion,  pleural  effusion  cytology  with  ancillary
methods  like  ICC  is  a  useful  tool  to  detect  malignant  effu-
sions  and  to  suggest  the  type  and  the  possible  primary  site
of  the  tumor.
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